Mizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-term

August 11, 2023
Mizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-termMizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-term

Jared Holz, Mizuho healthcare strategist, joins ‘Squawk Box’ to discuss Novo Nordisk’s quarterly earnings results, which hiked its outlook for 2023 after reporting a 30% increase in sales for the first half of the year, powered by strong demand for its weight loss drugs, and more.

Share This

Latest Mizuho News

OpenAI vs. Anthropic: the IPO battle that could define the future of AI investing

OpenAI vs. Anthropic: the IPO battle that could define the future of AI investing

April 1, 2026
Biopharma thesis starting to move away from obesity drugs, says Mizuho’s Jared Holz

Biopharma thesis starting to move away from obesity drugs, says Mizuho’s Jared Holz

March 20, 2026
Mizuho Securities Analyst on Latest with Oil and Gas Amid Middle East Conflict

Mizuho Securities Analyst on Latest with Oil and Gas Amid Middle East Conflict

March 13, 2026

Mizuho news from around the globe

back-to-top-blue